VINBLASTINE IN METASTATIC RENAL-CELL CARCINOMA - EORTC PHASE-II TRIAL-30882

被引：27

作者：

FOSSA, SD

DROZ, JP

PAVONEMACALUSO, MM

DEBRUYNE, FJJ

VERMEYLEN, K

SYLVESTER, R

机构：

[1] UNIV HOSP NIJMEGEN,NIJMEGEN,NETHERLANDS

[2] UNIV HOSP PALERMO,DEPT UROL,PALERMO,ITALY

[3] INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE

来源：

EUROPEAN JOURNAL OF CANCER | 1992年 / 28A卷 / 4-5期

关键词：

D O I：

10.1016/0959-8049(92)90139-S

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

32 patients with metastatic renal cell carcinoma (MRCC) who had had no prior chemotherapy received vinblastine 0.15 mg/kg intravenously once weekly for 6 weeks, thereafter every second week, provided no major toxicity. Dose modifications were based on haematological and neurological side-effects. Only one complete response was observed among 26 evaluable patients (response rate: 4%; 95% confidence interval: 0-20%). 4 out of 29 patients developed grade 3 leukopenia. Grade 3 peripheral neurotoxicity was recorded in 2 patients. 2 patients had grade 3 alopecia. Vinblastine has no major significance on the clinical management of MRCC.

引用

页码：878 / 880

页数：3

共 11 条

[1] PHASE-II STUDY OF 5-DAY CONTINUOUS INFUSION OF VINBLASTINE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA [J].

CRIVELLARI, D ;

TUMOLO, S ;

FRUSTACI, S ;

GALLIGIONI, E ;

FIGOLI, F ;

LORE, G ;

VERONESI, A ;

MONFARDINI, S .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (03) :231-233

[2]

FOSSA SD, IN PRESS WORLD J URO

[3] CURRENT STATUS OF THERAPY OF ADVANCED RENAL CARCINOMA [J].

HRUSHESKY, WJ ;

MURPHY, GP .

JOURNAL OF SURGICAL ONCOLOGY, 1977, 9 (03) :277-288

[4] EVALUATION OF CHEMOTHERAPEUTIC-AGENTS IN A NEW MURINE RENAL CARCINOMA MODEL [J].

HRUSHESKY, WJ ;

MURPHY, GP .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 52 (04) :1117-1122

[5]

MARSONI S, 1970, CLIN DRUG DEV ANAL P

[6]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[7]

2-6

[8] A PROGRESS REPORT ON THE TREATMENT OF 157 PATIENTS WITH ADVANCED CANCER USING LYMPHOKINE-ACTIVATED KILLER-CELLS AND INTERLEUKIN-2 OR HIGH-DOSE INTERLEUKIN-2 ALONE [J].

ROSENBERG, SA ;

LOTZE, MT ;

MUUL, LM ;

CHANG, AE ;

AVIS, FP ;

LEITMAN, S ;

LINEHAN, WM ;

ROBERTSON, CN ;

LEE, RE ;

RUBIN, JT ;

SEIPP, CA ;

SIMPSON, CG ;

WHITE, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (15) :889-897

[9]

SOMMER HH, 1985, CANCER CHEMOTH PHARM, V14, P277

[10]

STOTER G, 1980, CANCER CHEMOTHERAPY, V2, P315

← 1 2 →